ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review

Allergy. 2008 Jun;63(6):660-9. doi: 10.1111/j.1398-9995.2008.01649.x.


Allergic diseases constitute a global health problem, as they have an increasing economic and social impact and, especially, they can deeply interfere with the patients' daily life, being a cause of physical and emotional discomfort. This is why the health-related quality-of-life (HRQoL) has become increasingly important in health care research; in fact, the assessment of the impact the disease and its treatment have on patients, provides a more comprehensive approach in outcome evaluation. Numerous validated questionnaires are available and many studies have been performed evaluating HRQoL in people affected by allergic rhinitis (AR), thus testifying a great interest in this topic. The aims of the present review are: to examine the scientific literature of the last 3 years dealing with the impact of AR treatments suggested by allergic rhinitis and its impact on asthma guidelines on patients' QoL, and to identify the unexplored or not-fully-investigated areas concerning this issue.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Allergic Agents / administration & dosage
  • Anti-Allergic Agents / therapeutic use*
  • Cost of Illness
  • Desensitization, Immunologic
  • Drug Administration Routes
  • Health Services Research
  • Humans
  • Immunotherapy
  • Quality of Life*
  • Randomized Controlled Trials as Topic
  • Rhinitis, Allergic, Perennial / drug therapy*
  • Rhinitis, Allergic, Seasonal / drug therapy*
  • Surveys and Questionnaires


  • Anti-Allergic Agents